MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Multimodal MRI markers modifications in multiple system atrophy: A longitudinal study

P. Péran, WG. Meissner, O. Rascol, A. Pavy-Le Traon (Toulouse, France)

Meeting: 2018 International Congress

Abstract Number: 181

Keywords: Multiple system atrophy(MSA): Pathophysiology

Session Information

Date: Saturday, October 6, 2018

Session Title: Neuroimaging (Non-PD)

Session Time: 1:45pm-3:15pm

Location: Hall 3FG

Objective: Using multimodal MRI, the aim of the study was to evaluate brain changes due to disease progression in multiple system atrophy (MSA) patients.

Background: Multimodal MRI approach is based on combination of MRI parameters sensitive to different tissue characteristics (e.g. volume atrophy, iron deposition, and microstructural damage). The combination of different MR biomarkers could help to discriminate different pathologies with parkinsonian syndrome (Péran et al. Mov Disord.; 2018).

Methods: 19 MSA patients underwent 3-T MRI exam twice at time of inclusion and after one year of follow-up. This MRI comprised: T2*-weighted, T1-weighted and diffusion tensor imaging scans. We used the same method as in the previous work (Péran et al., Brain, 2010) to extract MRI markers (grey density, R2* value, mean diffusity (MD) and fractional anisotropy). The GD, R2*, MD, and FA maps were compared using non-parametric paired t-tests. Statistical significance threshold was set to p<.05 corrected for family wise error.

Results: [figure1] shows changes due to disease progression from voxel-based analysis in R2*, MD and FA maps. The main results showed significant increase of MD in brainstem and in cerebellum in MSA patients. After one year, MSA patients showed also lower FA mainly in left inferior longitudinal fasciculus. Additionally, MSA patients showed a decrease of R2* mainly in cerebellum and in fusiform gyrus. We did not find significant modifications for grey density maps. (Figure1: Significant differences in R2* (red); MD (green) and FA (blue) maps.)

Conclusions: This study demonstrates that multimodal MRI is able to detect longitudinal modifications after one year of MSA progression. Further analyses are on-going to determine the relationships between clinical and MRI markers.

References: 1: Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O. MRI supervised and unsupervised classification of Parkinson’s disease and multiple system atrophy. Mov Disord. 2018 Feb 23. doi: 10.1002/mds.27307. [Epub ahead of print] PubMed PMID: 29473662. 2: Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri FE, Caltagirone C, Spalletta G, Sabatini U. Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain. 2010 Nov;133(11):3423-33. doi:10.1093/brain/awq212.

To cite this abstract in AMA style:

P. Péran, WG. Meissner, O. Rascol, A. Pavy-Le Traon. Multimodal MRI markers modifications in multiple system atrophy: A longitudinal study [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/multimodal-mri-markers-modifications-in-multiple-system-atrophy-a-longitudinal-study/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/multimodal-mri-markers-modifications-in-multiple-system-atrophy-a-longitudinal-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley